University of Hawai‘i at Manoa Homepage

Faculty

Jonathan K. Cho, MD

Jonathan K. Cho, MD
  • Clinical Member
    Translational andClinical Research
    University of Hawaii Cancer Center
  • Chair
    Data and Safety Monitoring Committee
    Translational and Clinical Research
    Universityof Hawaii Cancer Center
  • Academic Appointments

  • Adjunct Professor
    University of Hawaii Cancer Center
    University of Hawaii at Manoa
  • Assistant Clinical Professor of Medicine
    John A. Burns School of Medicine
    University of Hawaii at Manoa

Degrees

  • MD
    John A. Burns School of Medicine
    University of Hawaii at Manoa

Research Focus

Dr. Cho has served as the Principal Investigator (PI) of the NCI-funded Hawaii Minority/ Underserved NCI Community Oncology Research Program (NCORP) at the University of Hawaii Cancer Center. He has been a faculty member of the UH Cancer Center since 1991. Dr. Cho helped expand the infrastructure of clinical trial activities at the UH Cancer Center allowing the conduct of both investigator-initiated translational sciences and pharmaceutical-sponsored trials. He is currently the PI of various pharmaceutical-sponsored oncology trials at the Cancer Center. He is also involved in developing the clinical trials activity of the Hawaii Cancer Consortium.

Selected Publications

  • Budd G, Barlow W, Moore H, Hobday T, Stewart J, Issacs C, Salim M, Cho J, Rinn., Albain K, Chew H, Burton G, Moore T, Srkalovic G, McGregor B, Flaherty L, Livington R, Lew D, Gralow J, Hortobagyl G. (2014). SWOG S0221: A Phase III Trial Comparing Chemotherapy Schedules in High-Risk, Early Stage Breast Cancer. J. Clinical Oncology.2014.56-3296.
  • Cho JK. (2008). International Association for the Study of Lung Cancer- The Lung Cancer Staging Project, Hawaii Med J, 67(8) 220-222.
  • Cho JK. (2003). Lung Cancer Treatment: Present and Future. Hawaii Med J, 63(2):61-2.
  • Ross HJ, Cho JK, Osann K, Wong SP. et al. (1997). Phase I/II trial of low-dose Cyclosporin A with EP for advanced non-small-cell 1ung cancer. Lung Cancer, 1:1-10.(1995).
  • Cho JK, Lee Y, Lutzky J, Redpath L, Slater L. (1995). Collateral Sensitivity to Radiation and Cis-Platinum in a Multidrug Resistant Human Leukemia Cell Line. Cancer Chemotherapy Pharmacol. 37:168-172.
  • Singh D, Doroshow J II, Leong L, Margolin K, Akman S, Raschko J, Somlo G, Morgan R, Harrison J, Cho JK, Ahn C. (1992). Phase II Trial of 5-FIuorouracil, High-Dose Leucovorin, Calcium, and Dipyridamole in Advanced Prostate Cancer. Cancer Research Clinical Oncology, 119:117-120.

Publication list via PubMed

Active Trials

  • J. Cho,Sub-Investigator
    ML25749, Combination Immunotherapy with Herceptin and the HER2
    Vaccine E75 in Low and Intermediate HER2-Expressing Breast Cancer Patients to Prevent Recurrence
    2014 - present
  • J. Cho, Principal Investigator
    PUMA-NER-1301, A Study ofNertinib plus Capecitabine versus Lapatinib plus Capecitabine in Patients with HER2+ Metastatic Breast Cancer who have Received Two or More Prior HER2-Directed Regimens in the Metastatic Setting (NALA)
    2014 – present
  • J. Cho, Sub-Investigator
    C16014, A Phase 3, Randomized, Double-Blind Multicenter Study Comparing Oral MLN9708 plus Lenalidomide and Dexamethasone versus Placebo plus Lenalidomide and Dexamethasone in Adult Patients with Newly Diagnosed Multiple Myeloma
    2010 - present
  • J. Cho, Principal Investigator
    CRCH 0901, CHS 16940: Prospective, Randomized, Single-Blinded, Multi-Center Phase TI Trial of the HER2/neu Peptide GP2 + GM-CSF Vaccine versus GM­ CSF Alone in HLA-A2+ OR the Modified HER2/neu Peptide AE37 + GM-CSF Vaccine versus GM-CSF Alone in HLA-A2-Node- Positive and High Risk Node-Negative Breast Cancer Patients to Prevent Recurrence
    2010 – present